Impact of Preoperative Quadratus Lumborum Block on Postoperative Opioid Consumption After Laparoscopic Hysterectomy
Launched by WALTER REED NATIONAL MILITARY MEDICAL CENTER · Nov 25, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a technique called the quadratus lumborum (QL) block, which is a type of nerve block, to see if it can help manage pain better during and after laparoscopic hysterectomy surgery. The main goal is to find out if using this nerve block reduces the amount of pain medication needed during and after the surgery compared to the standard method of using a local numbing medicine at the incision sites. Women aged 18 and older who are scheduled for a laparoscopic hysterectomy and can understand English may be eligible to participate.
If you join the trial, you will be randomly assigned to one of two groups: one group will receive the QL block plus a placebo (a harmless saline solution) at the incision sites, while the other will get the QL block with the local numbing medicine at the incision sites. You will have a few standard appointments, including visits before and after the surgery, and you will need to fill out some quick questionnaires about your pain at various times after the surgery. This study is not yet recruiting participants, but it aims to improve pain management for women undergoing this type of surgery.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • scheduled to undergo laparoscopic hysterectomy
- • able to speak and understand English
- • DEERs eligible (eligible for healthcare within military heath system)
- • Owning a phone that can receive text messages or having internet access to complete questionnaires
- Exclusion Criteria:
- • pre-operative opioid use
- • pre-operative pain management clinic patient
- • planned concomitant prolapse or incontinence procedure
- • planned concomitant non-gynecologic abdominal procedure (i.e. hernia repair)
- • inability to receive liposomal or non-liposomal bupivacaine
- • inability to receive non-steroidal anti-inflammatory drugs (NSAIDs)
- • inability to receive acetaminophen
- • inability to receive oxycodone
- • QL block not able to be performed bilaterally
- • planned or performed mini-laparotomy (incision greater than 2cm)
- • case converted to laparotomy
About Walter Reed National Military Medical Center
Walter Reed National Military Medical Center (WRNMMC) is a premier medical facility dedicated to providing comprehensive healthcare services to military personnel, their families, and veterans. As a leader in clinical research and trials, WRNMMC focuses on advancing medical knowledge and improving patient outcomes through innovative studies in various fields, including trauma care, infectious diseases, and rehabilitation. The center is committed to upholding the highest ethical standards in research while fostering collaboration among military and civilian healthcare professionals. Its mission is to enhance the health and well-being of service members and the broader community through cutting-edge research and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Kathryn A Edmonds, MD
Principal Investigator
Walter Reed National Military Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported